◎ Sugi Atlas

Atlas / Gene / SIGLEC15

SIGLEC15

gene
On this page

Also known as HsT1361

Summary

SIGLEC15 (sialic acid binding Ig like lectin 15, HGNC:27596) is a protein-coding gene on chromosome 18q21.1, encoding Sialic acid-binding Ig-like lectin 15 (Q6ZMC9). Binds sialylated glycoproteins.

Predicted to be involved in regulation of actin cytoskeleton organization; regulation of bone resorption; and regulation of osteoclast development. Predicted to be located in membrane. Predicted to be part of protein-containing complex. Predicted to be active in plasma membrane.

Source: NCBI Gene 284266 — RefSeq curated summary.

At a glance

  • GWAS associations: 2
  • Clinical variants (ClinVar): 3 total
  • Druggable target: yes
  • MANE Select transcript: NM_213602

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:27596
Approved symbolSIGLEC15
Namesialic acid binding Ig like lectin 15
Location18q21.1
Locus typegene with protein product
StatusApproved
AliasesHsT1361
Ensembl geneENSG00000197046
Ensembl biotypeprotein_coding
OMIM618105
Entrez284266

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000389474, ENST00000546268, ENST00000587418, ENST00000593178, ENST00000602118

RefSeq mRNA: 1 — MANE Select: NM_213602 NM_213602

CCDS: CCDS32819

Canonical transcript exons

ENST00000389474 — 6 exons

ExonStartEnd
ENSE000014304124582567545825780
ENSE000015059634583751345837896
ENSE000034608884584210645844094
ENSE000034666704583702945837088
ENSE000037161784584021145840241
ENSE000037393054583871845839095

Expression profiles

Bgee: expression breadth ubiquitous, 137 present calls, max score 86.41.

FANTOM5 (CAGE): breadth broad, TPM avg 2.8173 / max 90.9316, expressed in 546 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter IDTPM avgSamples expressed
1701341.1512244
1701350.4766180
1701320.4425166
1701330.2886130
1701310.1894100
1701300.134656
1701360.134483

Top tissues by expression

222 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
jejunal mucosaUBERON:000039986.41gold quality
buccal mucosa cellCL:000233684.58gold quality
periodontal ligamentUBERON:000826683.96gold quality
pancreatic ductal cellCL:000207982.01gold quality
tibiaUBERON:000097980.27gold quality
jejunumUBERON:000211577.50gold quality
duodenumUBERON:000211477.07gold quality
amniotic fluidUBERON:000017376.82silver quality
diaphragmUBERON:000110376.44gold quality
olfactory bulbUBERON:000226475.72silver quality
mononuclear cellCL:000084274.77gold quality
monocyteCL:000057674.73gold quality
leukocyteCL:000073874.46gold quality
mammary ductUBERON:000176574.24silver quality
hair follicleUBERON:000207374.05gold quality
tongue squamous epitheliumUBERON:000691973.76gold quality
epithelium of mammary glandUBERON:000324473.70silver quality
mucosa of urinary bladderUBERON:000125973.65silver quality
male germ line stem cell (sensu Vertebrata) in testisCL:0000089 ∩ UBERON:000047373.10gold quality
epithelium of nasopharynxUBERON:000195172.44gold quality
epithelial cell of pancreasCL:000008372.21silver quality
mucosa of paranasal sinusUBERON:000503071.04gold quality
corpus epididymisUBERON:000435970.97silver quality
caput epididymisUBERON:000435869.93gold quality
nasal cavity epitheliumUBERON:000538469.87gold quality
cervix squamous epitheliumUBERON:000692269.59gold quality
substantia nigra pars reticulataUBERON:000196668.56silver quality
endothelial cellCL:000011568.35silver quality
vastus lateralisUBERON:000137968.19gold quality
quadriceps femorisUBERON:000137768.15gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

ExperimentMarker?Max mean expression
E-CURD-112yes16.27
E-MTAB-10042yes9.55
E-ANND-3yes3.22

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

17 targeting SIGLEC15, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-7110-3P100.0073.182486
HSA-MIR-6873-3P100.0071.422626
HSA-MIR-8485100.0077.574731
HSA-MIR-3912-5P99.9566.11925
HSA-MIR-6817-3P99.7968.352126
HSA-MIR-129999.7771.242389
HSA-MIR-4677-5P99.7070.091940
HSA-MIR-7152-5P99.6069.332094
HSA-MIR-312899.5067.851258
HSA-MIR-6739-3P99.2268.841843
HSA-MIR-6510-5P99.1466.591081
HSA-MIR-9851-5P97.5767.491067
HSA-MIR-625-3P97.3266.55554
HSA-MIR-6823-3P95.4566.14704
HSA-MIR-2114-3P95.4566.11579
HSA-MIR-6750-5P93.9466.68797
HSA-MIR-6822-5P93.9466.34812

Literature-anchored findings (GeneRIF, showing 39)

  • Siglec-15 recognizes the tumoral sTn antigen and transduces a signal for enhanced TGF-beta secretion in TAMs (PMID:23035012)
  • Siglec-15 is a potential target for normalization cancer immunotherapy. (PMID:30833750)
  • hemical biology has advanced our understanding of the nature of Siglec-15 ligands, but the exact nature of Siglec-15 ligand depends on the biological context, leaving plenty of room for further exploration (PMID:31900164)
  • The diverse functions of Siglec-15 in bone remodeling and antitumor responses. (PMID:32112821)
  • Siglec-15 recognition of sialoglycans on tumor cell lines can occur independently of sialyl Tn antigen expression. (PMID:32501471)
  • The significance of Siglec-15 expression in resectable non-small cell lung cancer. (PMID:32749846)
  • LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma. (PMID:32780490)
  • N-glycosylation of Siglec-15 decreases its lysosome-dependent degradation and promotes its transportation to the cell membrane. (PMID:32921411)
  • Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis. (PMID:32939323)
  • Siglec-15 on Osteoclasts Is Crucial for Bone Erosion in Serum-Transfer Arthritis. (PMID:33020147)
  • Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients. (PMID:33441719)
  • Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. (PMID:33537076)
  • Immunopositivity for Siglec-15 in gastric cancer and its association with clinical and pathological parameters. (PMID:33666065)
  • Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells. (PMID:33951750)
  • Siglec-15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44. (PMID:34328657)
  • Siglec-15 promotes progression of clear renal cell carcinoma. (PMID:34561324)
  • SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. (PMID:35077803)
  • Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma. (PMID:35083884)
  • Identification and characterization of three Siglec15-related immune and prognostic subtypes of breast-invasive cancer. (PMID:35151947)
  • Long Noncoding RNA TUG1 Inhibits Tumor Progression through Regulating Siglec-15-Related Anti-Immune Activity in Hepatocellular Carcinoma. (PMID:35237695)
  • Knocking down Siglec-15 in osteosarcoma cells inhibits proliferation while promoting apoptosis and pyroptosis by targeting the Siglec-15/STAT3/Bcl-2 pathway. (PMID:35398779)
  • Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma. (PMID:35729260)
  • Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma. (PMID:35769818)
  • Unveiling the molecular features, relevant immune and clinical characteristics of SIGLEC15 in thyroid cancer. (PMID:36159823)
  • Siglec-15 as multifunctional molecule involved in osteoclast differentiation, cancer immunity and microbial infection. (PMID:36265694)
  • Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone. (PMID:36290882)
  • Significance of Siglec-15 expression in colorectal cancer: association with advanced disease stage and fewer tumor-infiltrating lymphocytes. (PMID:36424637)
  • Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: Bioinformatics Analysis and Clinicopathological Evidence. (PMID:36438917)
  • Transcriptional Regulation of Siglec-15 by ETS-1 and ETS-2 in Hepatocellular Carcinoma Cells. (PMID:36614238)
  • Siglec15 promotes the migration of thyroid carcinoma cells by enhancing the EGFR protein stability. (PMID:37129515)
  • Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma. (PMID:37234161)
  • Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b. (PMID:37311743)
  • Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas. (PMID:37325664)
  • Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. (PMID:37465593)
  • Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas. (PMID:37674198)
  • Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer. (PMID:37843557)
  • Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma. (PMID:38072971)
  • Siglec-15 regulates cell proliferation, migration and invasion in bladder cancer. (PMID:38169162)
  • SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. (PMID:38988824)

Cross-species orthologs

3 orthologs

OrganismSymbolGene ID
danio_reriobckdhblENSDARG00000093569
mus_musculusSiglec15ENSMUSG00000091055
rattus_norvegicusSiglec15ENSRNOG00000033588

Paralogs (16): CD22 (ENSG00000012124), SIGLEC1 (ENSG00000088827), SIGLEC8 (ENSG00000105366), CD33 (ENSG00000105383), SIGLEC6 (ENSG00000105492), MAG (ENSG00000105695), SIGLEC9 (ENSG00000129450), SIGLEC10 (ENSG00000142512), TMEM25 (ENSG00000149582), SIGLEC11 (ENSG00000161640), SIGLEC16 (ENSG00000161643), SIGLEC7 (ENSG00000168995), SIGLECL1 (ENSG00000179213), SIGLEC14 (ENSG00000254415), SIGLEC12 (ENSG00000254521), SIGLEC5 (ENSG00000268500)

Protein

Protein identifiers

Sialic acid-binding Ig-like lectin 15 — Q6ZMC9 (reviewed: Q6ZMC9)

Alternative names: CD33 antigen-like 3

All UniProt accessions (2): Q6ZMC9, K7EN40

UniProt curated annotations — full annotation on UniProt →

Function. Binds sialylated glycoproteins.

Subunit / interactions. Interacts with TYROBP and HCST.

Subcellular location. Membrane.

Tissue specificity. Expressed in macrophage and/or dendritic cells of spleen and lymph nodes.

Similarity. Belongs to the immunoglobulin superfamily. SIGLEC (sialic acid binding Ig-like lectin) family.

Isoforms (2)

UniProt IDNamesCanonical?
Q6ZMC9-11yes
Q6ZMC9-22

RefSeq proteins (1): NP_998767* (*=MANE)

Domains & families (InterPro)

IDNameType
IPR003599Ig_subDomain
IPR007110Ig-like_domDomain
IPR013106Ig_V-setDomain
IPR013783Ig-like_foldHomologous_superfamily
IPR036179Ig-like_dom_sfHomologous_superfamily
IPR042836SIG15Family

Pfam: PF07686

UniProt features (35 total): strand 12, disulfide bond 3, helix 3, splice variant 2, mutagenesis site 2, topological domain 2, domain 2, signal peptide 1, chain 1, glycosylation site 1, sequence variant 1, turn 1, transmembrane region 1, region of interest 1, compositionally biased region 1, binding site 1

Structure

Experimental structures (PDB)

1 structures.

PDBMethodResolution (Å)
7ZOZX-RAY DIFFRACTION2.1

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q6ZMC9-F178.320.57

Antibody-complex structures (SAbDab): 1 — 7ZOZ

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 143

Disulfide bonds (3): 64–142, 95–104, 187–237

Glycosylation sites (1): 172

Mutagenesis-validated functional residues (2):

PositionPhenotype
143abrogates glycan-binding.
274abrogates interaction with hcst and tyrobp.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

IDPathway
R-HSA-2172127DAP12 interactions
R-HSA-168249Innate Immune System
R-HSA-168256Immune System

MSigDB gene sets: 93 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_MYELOID_CELL_DEVELOPMENT, GOZGIT_ESR1_TARGETS_DN, GOBP_BONE_CELL_DEVELOPMENT, GOBP_MYELOID_LEUKOCYTE_DIFFERENTIATION, GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS, GOBP_REGULATION_OF_HEMOPOIESIS, GOBP_BONE_DEVELOPMENT, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, chr18q12, GOBP_REGULATION_OF_BONE_REMODELING, GOBP_MULTICELLULAR_ORGANISMAL_LEVEL_HOMEOSTASIS, GOBP_BONE_RESORPTION

GO Biological Process (3): regulation of actin cytoskeleton organization (GO:0032956), regulation of bone resorption (GO:0045124), regulation of osteoclast development (GO:2001204)

GO Molecular Function (0):

GO Cellular Component (3): plasma membrane (GO:0005886), protein-containing complex (GO:0032991), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

CategoryPathways
Innate Immune System1
Immune System1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
actin cytoskeleton organization1
regulation of actin filament-based process1
regulation of cytoskeleton organization1
bone resorption1
regulation of bone remodeling1
osteoclast development1
regulation of hemopoiesis1
membrane1
cell periphery1
cellular_component1
cellular anatomical structure1

Protein interactions and networks

STRING

644 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
SIGLEC15TYROBPO43914932
SIGLEC15EEF1A2P54266889
SIGLEC15SIGLEC1Q9BZZ2736
SIGLEC15CD22P20273727
SIGLEC15SIGLEC7Q9Y286637
SIGLEC15MAGP20916628
SIGLEC15HCSTQ9UBK5616
SIGLEC15FCER1GP30273601
SIGLEC15LAG3P18627597
SIGLEC15SIGLEC11Q96RL6595
SIGLEC15TIGITQ495A1593
SIGLEC15SIGLEC8Q9NYZ4585
SIGLEC15HAVCR2Q8TDQ0581
SIGLEC15PDCD1LG2Q9BQ51576
SIGLEC15CD274Q9NZQ7572

IntAct

13 interactions, top by confidence:

ABTypeScore
SIGLEC15CD33psi-mi:“MI:0915”(physical association)0.400
LILRB2SIGLEC15psi-mi:“MI:0915”(physical association)0.400
SIGLEC15MAGpsi-mi:“MI:0915”(physical association)0.400
CD33SIGLEC15psi-mi:“MI:0915”(physical association)0.400
SIGLEC15LRRC4Cpsi-mi:“MI:0915”(physical association)0.400
SIGLEC15SIGLEC10psi-mi:“MI:0915”(physical association)0.400
SIGLEC15SIGLEC14psi-mi:“MI:0915”(physical association)0.400
SIGLEC15SIGLEC15psi-mi:“MI:0915”(physical association)0.400
SIGLEC9SIGLEC15psi-mi:“MI:0915”(physical association)0.400
SIGLEC15UNC5Dpsi-mi:“MI:0915”(physical association)0.400

BioGRID (1): SIGLEC15 (Proximity Label-MS)

ESM2 similar proteins: A2A9Q0, A5PKD8, A9JSM3, D4A2Q0, E7ERA6, F1SAM7, F2Z333, P0CG25, Q07303, Q0IIA6, Q1RMK9, Q24JP5, Q2MJR0, Q2WF71, Q3MIP1, Q3UV16, Q3ZCQ3, Q504Y2, Q5EBM0, Q5GH56, Q5GH64, Q5GH72, Q5RJI4, Q5SZI1, Q641Q3, Q6IEE6, Q6IQX7, Q6P6N5, Q6UKI2, Q6ZMC9, Q6ZVW7, Q86UD0, Q8IUW3, Q8IZ52, Q8K064, Q8N4K4, Q8NAC3, Q8NBR0, Q8NCL9, Q8NFR9

Diamond homologs: A6NMB1, O15389, O43699, P20138, Q08ET2, Q460M5, Q63994, Q64JA4, Q6ZMC9, Q80TG9, Q80ZE3, Q8N7X8, Q91Y57, Q920G3, Q95LH0, Q96LC7, Q96PQ1, Q96RL6, Q9BE71, Q9NYZ4, Q9ULH4, Q9Y286, Q9Y336, B4HY03, B4Q599, P98160, Q13046, Q8WZ42, Q96D42, O46598, O54947, P0C0K5, Q5FVR0, Q5QNS5, Q6U7R4, Q8R183, Q8TDQ0, Q8VIM0, Q96H15

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

3 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance1
Likely benign1
Benign1

Top pathogenic / likely-pathogenic (0)

SpliceAI

842 predictions. Top by Δscore:

VariantEffectΔscore
18:45839092:CCAG:Cdonor_loss1.0000
18:45839093:CAG:Cdonor_loss1.0000
18:45839097:T:Adonor_loss1.0000
18:45840197:T:Aacceptor_gain1.0000
18:45840209:A:AGacceptor_gain1.0000
18:45840210:G:GAacceptor_gain1.0000
18:45840210:GA:Gacceptor_gain1.0000
18:45840210:GAGC:Gacceptor_gain1.0000
18:45840240:CGG:Cdonor_loss1.0000
18:45840242:G:Adonor_loss1.0000
18:45840242:G:GGdonor_gain1.0000
18:45842103:CA:Cacceptor_loss1.0000
18:45837859:C:Gdonor_gain0.9900
18:45837910:G:GTdonor_gain0.9900
18:45837961:GGC:Gdonor_gain0.9900
18:45839094:AGGTG:Adonor_gain0.9900
18:45840206:CACA:Cacceptor_loss0.9900
18:45840207:A:AGacceptor_gain0.9900
18:45840208:C:Gacceptor_gain0.9900
18:45840208:CA:Cacceptor_loss0.9900
18:45840208:CAG:Cacceptor_gain0.9900
18:45840209:A:ATacceptor_loss0.9900
18:45840209:AGA:Aacceptor_gain0.9900
18:45840210:G:Cacceptor_loss0.9900
18:45840210:GAG:Gacceptor_gain0.9900
18:45840210:GAGCA:Gacceptor_gain0.9900
18:45840237:CCACG:Cdonor_gain0.9900
18:45840239:ACG:Adonor_gain0.9900
18:45840240:CG:Cdonor_gain0.9900
18:45840241:GG:Gdonor_gain0.9900

AlphaMissense

2094 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
18:45837643:G:CW81C0.998
18:45837643:G:TW81C0.998
18:45837678:T:GF93C0.997
18:45837828:G:CR143P0.995
18:45838780:T:AC187S0.995
18:45838781:G:CC187S0.995
18:45838818:G:CW199C0.995
18:45838818:G:TW199C0.995
18:45837532:G:CW44C0.994
18:45837532:G:TW44C0.994
18:45837590:T:AC64S0.994
18:45837591:G:AC64Y0.994
18:45837591:G:CC64S0.994
18:45837824:T:AC142S0.994
18:45837825:G:AC142Y0.994
18:45837825:G:CC142S0.994
18:45837592:C:GC64W0.993
18:45837596:T:CF66L0.993
18:45837597:T:GF66C0.993
18:45837598:C:AF66L0.993
18:45837598:C:GF66L0.993
18:45837641:T:AW81R0.993
18:45837641:T:CW81R0.993
18:45837677:T:CF93L0.993
18:45837678:T:CF93S0.993
18:45837679:C:AF93L0.993
18:45837679:C:GF93L0.993
18:45837752:G:TG118C0.992
18:45837826:C:GC142W0.992
18:45838930:T:AC237S0.992

dbSNP variants (sampled 300 via entrez): RS1000135281 (18:45829617 AC>A,ACC), RS1000146526 (18:45828474 G>A), RS1000192772 (18:45841457 G>C), RS1000679785 (18:45834381 C>T), RS1000846482 (18:45833184 T>C,G), RS1001119943 (18:45827117 C>T), RS1001417771 (18:45828874 G>A), RS1001494565 (18:45836106 G>A,T), RS1001551477 (18:45827267 T>C), RS1001774794 (18:45829677 T>C), RS1001806581 (18:45829053 A>C,G), RS1001899255 (18:45834078 T>C), RS1001971517 (18:45839629 G>A), RS1002359766 (18:45833695 CAA>C,CA), RS1002406010 (18:45827893 A>G)

Disease associations

OMIM: gene MIM:618105 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

StudyTraitp-value
GCST010538_9Sum of carotid plaque area5.000000e-06
GCST010539_8Sum of stenosis3.000000e-07

EFO canonical traits (1, from GWAS)

EFO IDTrait name
EFO:0006501carotid plaque build

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523355 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — SIGLECs (conserved)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

ChemicalActions (top 5)PubMed papers
(+)-JQ1 compoundaffects cotreatment, decreases expression2
Benzo(a)pyreneincreases methylation, affects methylation2
Estradioldecreases expression, affects cotreatment2
Progesteroneaffects cotreatment, decreases expression2
sotorasibaffects cotreatment, decreases expression1
sodium arseniteincreases expression1
pentanalincreases expression1
perfluorooctane sulfonic acidincreases expression1
mirdametinibaffects cotreatment, decreases expression1
trametinibaffects cotreatment, decreases expression1
NVP-BKM120affects cotreatment, decreases expression1
Smokeincreases expression1
Cadmium Chlorideincreases expression1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL4368161BindingBinding affinity to recombinant human Fc-fused siglec-15 by fluorescence based glycan microarray analysisExpedient assembly of Oligo-LacNAcs by a sugar nucleotide regeneration system: Finding the role of tandem LacNAc and sialic acid position towards siglec binding. — Eur J Med Chem

Cellosaurus cell lines

4 cell lines: 2 spontaneously immortalized cell line, 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

CellosaurusNameCategorySex
CVCL_E6RQGenomeditech CHO-K1 H_SIGLEC15+TYROBPSpontaneously immortalized cell lineFemale
CVCL_E6UUGenomeditech HEK-293 H_SIGLEC15+TYROBPTransformed cell lineFemale
CVCL_E6WLGenomeditech MC-38 H_SIGLEC15+TYROBPCancer cell lineFemale
CVCL_XZ47CHO-K1 OS8-SIGLEC15Spontaneously immortalized cell lineFemale

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 79

This page pulls from 79 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgtopdb_interactiongwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot